LinkedUp, TianTi end le­gal dis­pute with Adimab over yeast-based an­ti­body plat­form

LinkedUp Bio­science and TianTi Bio­ther­a­peu­tics have re­solved their le­gal bat­tle with Adimab dat­ing back to 2020 con­cern­ing al­leged mis­use of trade se­crets.

The de­fen­dants, both based in Woburn, MA, inked an agree­ment un­der which Adimab’s law­suit “will be dis­missed with prej­u­dice,” with none of the par­ties ad­mit­ting wrong­do­ing. The case was orig­i­nal­ly filed at the Suf­folk Coun­ty Su­pe­ri­or Court in Mass­a­chu­setts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER